Metabolism of Estrogens: Turnover Differs between Platinum-Sensitive and -Resistant High-Grade Serous Ovarian Cancer Cells
Open Access
- 22 January 2020
- Vol. 12 (2), 279
- https://doi.org/10.3390/cancers12020279
Abstract
High-grade serous ovarian cancer (HGSOC) is currently treated with cytoreductive surgery and platinum-based chemotherapy. The majority of patients show a primary response; however, many rapidly develop drug resistance. Antiestrogens have been studied as low toxic treatment options for HGSOC, with higher response rates in platinum-sensitive cases. Mechanisms for this difference in response remain unknown. Therefore, the present study investigated the impact of platinum resistance on steroid metabolism in six established HGSOC cell lines sensitive and resistant against carboplatin using a high-resolution mass spectrometry assay to simultaneously quantify the ten main steroids of the estrogenic metabolic pathway. An up to 60-fold higher formation of steroid hormones and their sulfated or glucuronidated metabolites was observed in carboplatin-sensitive cells, which was reversible by treatment with interleukin-6 (IL-6). Conversely, treatment of carboplatin-resistant cells expressing high levels of endogenous IL-6 with the monoclonal anti-IL-6R antibody tocilizumab changed their status to “platinum-sensitive”, exhibiting a decreased IC50 value for carboplatin, decreased growth, and significantly higher estrogen metabolism. Analysis of these metabolic differences could help to detect platinum resistance in HGSOC patients earlier, thereby allowing more efficient interventions.Keywords
Funding Information
- Austrian Science Fund (I 3417-B31)
- European Union Seventh Framework Programe OCTIPS (279113, R.P.)
- Slovenian Research Agency (J3-8212)
This publication has 62 references indexed in Scilit:
- Ovarian cancer molecular pathologyCancer and Metastasis Reviews, 2012
- Inflammation and ovarian cancerCytokine, 2012
- Rethinking ovarian cancer: recommendations for improving outcomesNature Reviews Cancer, 2011
- Interleukin-6 as a Therapeutic Target in Human Ovarian CancerClinical Cancer Research, 2011
- Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian CancerClinical Cancer Research, 2010
- Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cellsCancer Letters, 2010
- Genevestigator V3: A Reference Expression Database for the Meta-Analysis of TranscriptomesAdvances in Bioinformatics, 2008
- Metabolism of resveratrol in breast cancer cell lines: Impact of sulfotransferase 1A1 expression on cell growth inhibitionCancer Letters, 2008
- Diagnostic open laparoscopy in the management of advanced ovarian cancerGynecologic Oncology, 2006
- Intratumoral Aromatase in Human Breast, Endometrial, and Ovarian MalignanciesEndocrine Reviews, 1998